Molecular basis for therapy resistance

Molecular Oncology

Volumn 4, Issue 3, 2010, Pages 284-300

  Lønning, Per E ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Chemoresistance; Microarray; p53; Prediction

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; GEFITINIB; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

APOPTOSIS; BREAST CANCER; CHEMOSENSITIVITY; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HIGH THROUGHPUT SCREENING; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; THERAPY RESISTANCE; TREATMENT FAILURE; UPREGULATION; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 77953869917     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.04.005     Document Type: Review

References (189)

1. Abe O., Abe R., Enomoto K., Kikuchi K., Koyama H., Masuda H., Nomura Y., Sakai K., Sugimachi K., Tominaga T., Uchino J., Yoshida M., Haybittle J.L., Davies C., Harvey V.J., Holdaway T.M., Kay R.G., Mason B.H., Forbes J.F., Wilcken N., Gnant M., Jakesz R., Ploner M., Yosef H.M.A., Focan C., Lobelle J.P., Peek U., Oates G.D., Powell J., Durand M., Mauriac L., Di Leo A., Dolci S., Piccart M.J., Masood M.B., Parker D., Price J.J., Hupperets P., Jackson S., Ragaz J., Berry D., Broadwater G., Cirrincione C., Muss H., Norton L., Weiss R.B., Abu-Zahra H.T., Portnoj S.M., Baum M., Cuzick J., Houghton J., Riley D., Gordon N.H., Davis H.L., Beatrice A., Mihura J., Naja A., Lehingue Y., Romestaing P., Dubois J.B., Delozier T., Mace-Lesec'h J., Rambert P., Andrysek O., Barkmanova J., Owen J.R., Meier P., Howell A., Ribeiro G.C., Swindell R., Alison R., Boreham J., Clarke M., Collins R., Darby S., Elphinstone P., Evans V., Godwin J., Gray R., Harwood C., Hicks C., James S., MacKinnon E., McGale P., McHugh T., Mead G., Peto R., Wang Y., Albano J., de Oliveira C.F., Gervasio H., Gordilho J., Johansen H., Mouridsen H.T., Gelman R.S., Harris J.R., Henderson I.C., Shapiro C.L., Andersen K.W., Axelsson C.K., et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
2. Aas T., Børresen A.-L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J.E., Akslen L.A., and Lønning P.E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2 (1996) 811-814
3. Aas T., Geisler S., Eide G.E., Haugen D.F., Varhaug J.E., Bassoe A.M., Thorsen T., Berntsen H., Borresen-Dale A.L., Akslen L.A., and Lonning P.E. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur. J. Cancer 39 (2003) 438-446
4. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., Ravdin P., Bugarini R., Boehner F.L., Davidson N.E., Sledge G.W., Winer E.P., Hudis C., Ingle J.N., Perez E.A., Pritchard K.I., Shepherd L., Gralow J.R., Yoshizawa C., Allred D.C., Osborne C.K., and Hayes D.F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11 (2010) 55-65
5. Audeh M.W., Penson R.T., Friedlander M.L., Powell B., Bell-McGuinn K.M., Scott C.G., Weitzel J.N., Carmichael J., and Tutt A. Phase II trial of the oral PARP inhibitor Olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. (Suppl.) 27 (2009) 277s Abstr 5500
6. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., Lecocke M., Metivier J., Booser D., Ibrahim N., Valero V., Royce M., Arun B., Whitman G., Ross J., Sneige N., Hortobagyi G.N., and Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22 (2004) 2284-2293
7. Bartlett J., Munro A.J., Dunn J., Hiller L., Twelves C., Cameron D., Thomas J., Campell F., Provenzano E., Pharoah P., Caldas C., Earl H., and Poole C. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: Emerging evidence from the UK NEAT adjuvant breast cancer trial. San Antonio Breast Cancer Symposium (2008)
8. Baselga J., Cortes J., Fumoleau P., Petrella T., Gelmon K., Verma S., Pivot X., Ross G., Szado T., and Gianni L. Pertuzumab and Trastuzumab: re-responses to 2 biological agents in patients with HER2-Positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Cancer Res. 69 (2009) 803S-804S
9. Benvenuti S., Frattini M., Arena S., Zanon C., Cappelletti V., Coradini D., Daidone M.G., Pilotti S., Pierotti M.A., and Bardelli A. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum. Mutat. 29 (2008) 284-288
10. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., de Vijver M.J.V., and Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
11. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., Martino S., Perez E.A., Muss H.B., Norton L., Hudis C., and Winer E.P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA: J. Am. Med. Assoc. 295 (2006) 1658-1667
12. Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., and de The H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360 (2002) 852-854
13. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Nasser V., Loriod W., Camerlo J., Tagett R., Tarpin C., Houvenaeghel G., Nguyen C., Maraninchi D., Jacquemier J., Houlgatte R., Birnbaum D., and Viens P. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 64 (2004) 8558-8565
14. Bertucci F., Tarpin C., Charafe-Jauffret E., Bardou V.J., Braud A.C., Tallet A., Gravis G., Viret F., Goncalves A., Houvenaeghel G., Blaise D., Jacquemier J., Maraninchi D., and Viens P. Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 33 (2004) 913-920
15. Bieche I., Lerebours F., Tozlu S., Espie M., Marty M., and Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin. Cancer Res. 10 (2004) 6789-6795
16. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., Olson Jr. J.A., Marks J.R., Dressman H.K., West M., and Nevins J.R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006) 353-357
17. Blackwell K.L., Pegram M.D., Tan-Chiu E., Schwartzberg L.S., Arbushites M.C., Maltzman J.D., Forster J.K., Rubin S.D., Stein S.H., and Burstein H.J. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann. Oncol. 20 (2009) 1026-1031
18. Bleeker F.E., Felicioni L., Buttitta F., Lamba S., Cardone L., Rodolfo M., Scarpa A., Leenstra S., Frattini M., Barbareschi M., Del Grammastro M., Sciarrotta M.G., Zanon C., Marchetti A., and Bardelli A. AKT1(E17K) in human solid tumours. Oncogene 27 (2008) 5648-5650
19. Bose P., and Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin. Investig. Drugs 18 (2009) 1735-1751
20. Bowen R.L., Duffy S.W., Ryan D.A., Hart I.R., and Jones J.L. Early onset of breast cancer in a group of British black women. Br. J. Cancer 98 (2008) 277-281
21. Browne B.C., O'Brien N., Duffy M.J., Crown J., and O'Donovan N. HER-2 signaling and inhibition in breast cancer. Curr. Cancer Drug Targets 9 (2009) 419-438
22. Burcombe R.J., Makris A., Richman P.I., Daley F.M., Noble S., Pittam M., Wright D., Allen S.A., Dove J., and Wilson G.D. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br. J. Cancer 92 (2005) 147-155
23. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., d'Assignies M.S., Bergh J., Lidereau R., Ellis P., Harris A., Bogaerts J., Therasse P., Floore A., Amakrane M., Piette F., Rutgers E., Sotiriou C., Cardoso F., and Piccart M.J. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98 (2006) 1183-1192
24. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., Mierzwa T., Szwiec M., Wisniowski R., Siolek M., Dent R., Lubinski J., and Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28 (2010) 375-379
25. Byrski T., Huzarski T., Dent R., Gronwald J., Zuziak D., Cybulski C., Kladny J., Gorski B., Lubinski J., and Narod S.A. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115 (2009) 359-363
26. Carey L.A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J. Clin. Oncol. 28 (2010) 361-363
27. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., and Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13 (2007) 2329-2334
28. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C.U., Nielsen T.O., Moorman P.G., Earp H.S., and Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA: J. Am. Med. Assoc. 295 (2006) 2492-2502
29. Carter H., Chen S.N., Isik L., Tyekucheva S., Velculescu V.E., Kinzler K.W., Vogelstein B., and Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 69 (2009) 6660-6667
30. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sorlie T., Dai H., He Y.D., van't Veer L.J., Bartelink H., van de Rijn M., Brown P.O., and van de Vijver M.J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3738-3743
31. Chang J., Powles T.J., Allred D.C., Ashey S.E., Clark G.M., Makris A., Assersohn L., Gregory R.K., Osborne C.K., and Dowsett M. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J. Clin. Oncol. 17 (1999) 3058-3063
32. Chang J., Wooten E., Tsimelzon A., Hilsenbeck S., Gutierrez M., Elledge R., Mohsin S.K., Osborne C., Chamness G., Allred D., and O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 (2003) 362-369
33. Cheang M.C.U., Chia S.K., Voduc D., Gao D.X., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., and Nielsen T.O. Ki67 Index, HER2 Status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 101 (2009) 736-750
34. Cheang M.C.U., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., and Nielsen T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype. Clin. Cancer Res. 14 (2008) 1368-1376
35. Chrisanthar R., Knappskog S., Løkkevik E., Anker G., Østenstad B., Lundgren S., Berge E.O., Risberg T., Mjaaland I., Maehle L., Engebretsen L., Lillehaug J.R., and Lønning P.E. CHEK2 mutations affecting kinase activity together with mutations in the TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS One 3 (2008) 1-15 e3062
36. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., and Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1999) 2639-2648
37. Colleoni M., Minchella I., Mazzarol G., Nole F., Peruzzotti G., Rocca A., Viale G., Orlando L., Ferretti G., Curigliano G., Veronesi P., Intra M., and Goldhirsch A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann. Oncol. 11 (2000) 1057-1059
38. Detre S., Salter J., Barnes D.M., Riddler S., Hills M., Johnston S.R.D., Gillett C., AHern R., and Dowsett M. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int. J. Cancer 81 (1999) 309-313
39. Di Stefano D., Mingazzini P.L., Scucchi L., Donnetti M., and Marinozzi V. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-6 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer 67 (1991) 463-471
40. Dnistrian A.M., Schwartz M.K., Fracchia A.A., Kaufman R.J., Hakes T.B., and Currie V.E. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer 51 (1983) 803-807
41. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., Cuzick J., Houghton J., Williams N., Mallon E., Bishop H., Ellis I., Larsimont D., Sasano H., Carder P., Cussac A.L., Knox F., Speirs V., Forbes J., and Buzdar A. Relationship Between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J. Clin. Oncol. 26 (2008) 1059-1065
42. Dressman H.K., Hans C., Bild A., Olson J.A., Rosen E., Marcom P.K., Liotcheva V.B., Jones E.L., Vujaskovic Z., Marks J., Dewhirst M.W., West M., Nevins J.R., and Blackwell K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12 (2006) 819-826
43. Ed, én P., Ritz C., Rose C., Fernö M., and Peterson C. "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur. J. Cancer 40 (2004) 1837-1841
44. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., Boyd J., Reis-Filho J.S., and Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
45. Ein-Dor L., Kela I., Getz G., Givol D., and Domany E. Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics 21 (2005) 171-178
46. Ellis M.J., Coop A., Singh B., Mauriac L., LlombertCussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., QuebeFehling E., and Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J. Clin. Oncol. 19 (2001) 3808-3816
47. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S.A., Nobel A.B., van't Veer L.J., and Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
48. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M.B., Jackson S.P., Smith G.C.M., and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
49. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., Andree S., Piccart M., Campone M., Brain E., MacGrogan G., Petit T., Jassem J., Bibeau F., Blot E., Bogaerts J., Aguet M., Bergh J., Iggo R., and Delorenzi M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15 (2009) 68-74
50. Finak G., Bertos N., Pepin F., Sadekova S., Souleimanova M., Zhao H., Chen H.Y., Omeroglu G., Meterissian S., Omeroglu A., Hallett M., and Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14 (2008) 518-527
51. Fisher B., Bauer M., Wickerham D.L., Redmond C.K., and Fisher E.R. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52 (1983) 1551-1557
52. Fisher B., Redmond C., Fisher E.R., and Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from national surgical adjuvant breast and bowel project protocol B-06. J. Clin. Oncol. 6 (1988) 1076-1087
53. Fisher E.R., Wang J.P., Bryant J., Fisher B., Mamounas E., and Wolmark N. Pathobiology of preoperative chemotherapy - Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer 95 (2002) 681-695
54. Flageng M.H., Moi L.L.H., Dixon J.M., Geisler J., Lien E.A., Miller W.R., Lonning P.E., and Mellgren G. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br. J. Cancer 101 (2009) 1253-1260
55. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., and de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361 (2009) 123-134
56. Geisler S., Børresen-Dale A.-L., Johnsen H., Aas T., Geisler J., Akslen L.A., Anker G., and Lønning P.E. TP53 gene mutations predict the response to neoadjuvant treatment with FUMI in locally advanced breast cancer. Clin. Cancer Res. 9 (2003) 5582-5588
57. Geisler S., Lønning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., Lillehaug J.R., Akslen L.A., and Borresen-Dale A.L. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61 (2001) 2505-2512
58. Gerdes J., Lelle R.J., Pickartz H., Heidenreich W., Schwarting R., Kurtsiefer L., Stauch G., and Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J. Clin. Pathol. 39 (1986) 977-980
59. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., Mariani G., Rodriguez J., Carcangiu M., Watson D., Valagussa P., Rouzier R., Symmans W.F., Ross J.S., Hortobagyi G.N., Pusztai L., and Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23 (2005) 7265-7277
60. Goldstein L.J., Gray R., Badve S., Childs B.H., Yoshizawa C., Rowley S., Shak S., Baehner F.L., Ravdin P.M., Davidson N.E., Sledge Jr. G.W., Perez E.A., Shulman L.N., Martino S., and Sparano J.A. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26 (2008) 4063-4071
61. Green M.D., Francis P.A., Gebski V., Harvey V., Karapetis C., Chan A., Snyder R., Fong A., Basser R., and Forbes J.F. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann. Oncol. 20 (2009) 1813-1817
62. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., Defazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., and Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
63. Gusterson B. Do 'basal-like' breast cancers really exist?. Nat. Rev. Cancer 9 (2009) 128-134
64. Hannemann J., Oosterkamp H.M., Bosch C.A.J., Velds A., Wessels L.F.A., Loo C., Rutgers E.J., Rodenhuis S., and van de Vijver M.J. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 23 (2005) 3331-3342
65. Harris L.N., Broadwater G., Abu-Khalaf M., Cowan D., Thor A.D., Budman D., Cirrincione C.T., Berry D.A., Winer E.P., Hudis C.A., Hayes D.F., Friedman P., Ellis M., and Dressler L. Topoisomerase II alpha amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J. Clin. Oncol. 27 (2009) 3430-3436
66. Harris L.N., You F.L., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., Ryan P.D., Come S.E., Burstein H.J., Lesnikoski B.A., Kamma M., Friedman P.N., Gelman R., Iglehart J.D., and Winer E.P. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13 (2007) 1198-1207
67. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17 (1999) 1474-1481
68. Hedenfalk I., Duggan D., Chen Y.D., Radmacher M., Bittner M., Simon R., Meltzer P., Gusterson B., Esteller M., Kallioniemi O.P., Wilfond B., Borg A., and Trent J. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
69. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z.Y., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., Backlund M.G., Yin Y.Z., Khramtsov A.I., Bastein R., Quackenbush J., Glazer R.I., Brown P.H., Green J.E., Kopelovich L., Furth P.A., Palazzo J.P., Olopade O.I., Bernard P.S., Churchill G.A., Van Dyke T., and Perou C.M. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8 (2007)
70. Hess K.R., Anderson K., Symmans W.F., Valero V., Ibrahim N., Mejia J.A., Booser D., Theriault R.L., Buzdar A.U., Dempsey P.J., Rouzier R., Sneige N., Ross J.S., Vidaurre T., Gomez H.L., Hortobagyi G.N., and Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24 (2006) 4236-4244
71. Hollestelle A., Nagel J.H., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., Ten Hagen T.L., de Leeuw B.H., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G., Dinjens W.N., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W., and Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res. Treat. (2009)
72. Horowitz J.M., Yandell D.W., Park S.H., Canning S., Whyte P., Buchkovich K., Harlow E., Weinberg R.A., and Dryja T.P. Point mutational inactivation of the retinoblastoma antioncogene. Science 243 (1989) 937-940
73. Hu Z.Y., Fan C., Oh D.S., Marron J.S., He X.P., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J.Y., Liu Y.D., Nanda R., Tretiakova M., Orrico A.R., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., and Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 (2006)
74. Hubert A., Mali B., Hamburger T., Rottenberg Y., Uziely B., Peretz T., and Kadouri L. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Familial Cancer 8 (2009) 173-177
75. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., Reed J., Krajewska M., Treilleux I., Rupin M., Magherini E., Mackey J., Martin M., and Vogel C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27 (2009) 1168-1176
76. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., Maeda E., Noguchi S., and Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23 (2005) 422-431
77. Jarvinen T.A.H., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., and Isola J. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156 (2000) 839-847
78. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., and Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27 (2009) 5538-5546
79. Jonat W., Maass H., Stolzenbach G., and Trams G. Estrogen receptor status and response to polychemotherapy in advanced breast cancer. Cancer 46 (1980) 2809-2813
80. Jordan V.C. The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - survival or death?. J. Clin. Oncol. 26 (2008) 3073-3082
81. Junttila T.T., Akita R.W., Parsons K., Fields C., Phillips G.D.L., Friedman L.S., Sampath D., and Sliwkowski M.X. Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941. Cancer Cell 15 (2009) 429-440
82. Kandioler-Eckersberger D., Ludwig C., Rudas M., Kappel S., Janschek E., Wenzel C., Schlagbauer-Wadl H., Mittlböck M., Gnant M., Steger G., and Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 6 (2000) 50-56
83. Karakas B., Bachman K.E., and Park B.H. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94 (2006) 455-459
84. Kaufman B., Trudeau M., Awada A., Blackwell K., Bachelot T., Salazar V., DeSilvio M., Westlund R., Zaks T., Spector N., and Johnston S. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+cohort in EGF103009, a phase II study. Lancet Oncol. 10 (2009) 581-588
85. Keet A.W.W., Al-Rafae M., Chappuis P.O., Brunet J.S., Ghadirian P., and Foulkes W.D. Long-term outcome after neo-adjuvant chemotherapy for breast cancer in BRCA1/2 carriers. Int. J. Cancer 125 (2009) 2236-2238
86. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., Schonau A., Gunnarsdottir K., Olsen K.E., Mouridsen H., and Ejlertsen B. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23 (2005) 7483-7490
87. Koster F., Engel J.B., Schally A.V., Honig A., Schroer A., Seitz S., Hohla F., Ortmann O., Diedrich K., and Buchholz S. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res. Treat. 116 (2009) 273-279
88. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., Buchholz T.A., Ross M.I., McNeese M.D., Buzdar A.U., Hortobagyi G.N., and Singletary S.E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17 (1999) 460-469
89. Kuroda N., Ohara M., Inoue K., Mizuno K., Fujishima N., Hamaguchi N., and Lee G.-H. The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med. Mol. Morphol. 42 (2009) 128-131
90. Kute T.E., Muss H.B., Hopkins M., Marshall R., Case D., and Kammire L. Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer. Breast Cancer Res. 6 (1985) 113-121
91. Lee C.W., Simin K., Liu Q., Plescia J., Guha M., Khan A., Hsieh C.C., and Altieri D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 10 (2008)
92. Lewis-Wambi J.S., and Jordan V.C. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?. Breast Cancer Res. 11 (2009)
93. Lewis J.S., Meeke K., Osipo C., Ross E.A., Kidawi N., Li T.Y., Bell E., Chandel N.S., and Jordan V.C. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J. Natl. Cancer Inst. 97 (2005) 1746-1759
94. Liedtke C., Hatzis C., Symmans W.F., Desmedt C., Haibe-Kains B., Valero V., Kuerer H., Hortobagyi G.N., Piccart-Gebhart M., Sotiriou C., and Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J. Clin. Oncol. 27 (2009) 3185-3191
95. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., Cristofanilli M., Hortobagyi G.N., and Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26 (2008) 1275-1281
96. Lin N.U., Claus E., Sohl J., Razzak A.R., Arnaout A., and Winer E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer high incidence of central nervous system metastases. Cancer 113 (2008) 2638-2645
97. Lippman M., Bolan G., and Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36 (1976) 4595-4601
98. Lippman M.E., Allegra J.C., Thompson E.B., Simon R., Barlock A., Green L., Huff K.K., Do H.M.T., Aitken S.C., and Warren R. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N. Engl. J. Med. 298 (1978) 1223-1228
99. Lipton A., Ali S.M., Leitzel K., Demers L., Chinchilli V., Engle L., Harvey H.A., Brady C., Nalin C.M., Dugan M., Carney W., and Allard J. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J. Clin. Oncol. 20 (2002) 1467-1472
100. Liu L., Greger J., Shi H., Liu Y., Greshock J., Annan R., Halsey W., Sathe G.M., Martin A.M., and Gilmer T.M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69 (2009) 6871-6878
101. Lord C.J., and Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8 (2008) 363-369
102. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
103. Lundin J., Lundin M., Holli K., Kataja V., Elomaa L., Pylkkanen L., TurpeenniemiHujanen T., and Joensuu H. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: Results from a nationwide study. J. Clin. Oncol. 19 (2001) 28-36
104. Lønning P. Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncol. 4 (2003) 177-185
105. Lønning P.E. Genes causing inherited cancer as beacons identifying the mechanisms of chemoresistance. Trends Mol. Med. 10 (2004) 113-118
106. Lønning P.E. Breast cancer prognostication and prediction; are we making progress?. Ann. Oncol. 18 Suppl 8 (2007) viii3-viii7
107. Lønning P.E., Knappskog S., Staalesen V., Chrisanthar R., and Lillehaug J.R. Breast cancer prognostication and prediction in the postgenomic era. Ann. Oncol. 18 (2007) 1293-1306
108. Lønning P.E., and Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit. Rev. Oncol./Haematol. 21 (1995) 158-193
109. Lønning P.E., Sørlie T., and Børresen-Dale A.-L. Genomics in breast cancer - therapeutic implications?. Nat. Clin. Pract. Oncol. 2 (2005) 26-33
110. Lønning P.E., Taylor P.D., Anker G., Iddon J., Wie L., Jorgensen L.M., Mella O., and Howell A. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 67 (2001) 111-116
111. Ma X.J., Wang Z.C., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J.T., Tran Y., Tran D., Tassin A., Amon P., Wang W., Enright E., Stecker K., Estepa-Sabal E., Smith B., Younger J., Balis U., Michaelson J., Bhan A., Habin K., Baer T.M., Brugge J., Haber D.A., Erlander M.G., and Sgroi D.C. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 (2004) 607-616
112. Martin S.A., Lord C.J., and Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genetics Develop. 18 (2008) 80-86
113. Masamura S., Santner S.J., Heitjan D.F., and Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80 (1995) 2918-2925
114. Migliaccio I., Gutierrez M.C., Wu M.F., Wong H., Pavlick A., Hilsenlbeck S.G., Horlings H.M., Rimawi M., Berns K., Bernards R., Osborne C.K., Arteaga C.L., and Chang J.C. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). Cancer Res. 69 (2009) 71S-72S
115. Miki Y., Swensen J., Shattuckeidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q.Y., Cochran C., Bennett L.M., Ding W., Bell R., Rosenthal J., Hussey C., Tran T., McClure M., Frye C., Hattier T., Phelps R., Haugenstrano A., Katcher H., Yakumo K., Gholami Z., Shaffer D., Stone S., Bayer S., Wray C., Bogden R., Dayananth P., Ward J., Tonin P., Narod S., Bristow P.K., Norris F.H., Helvering L., Morrison P., Rosteck P., Lai M., Barrett J.C., Lewis C., Neuhausen S., Cannonalbright L., Goldgar D., Wiseman R., Kamb A., and Skolnick M.H. A strong candidate for the breast and ovarian-cancer susceptibility gene brca1. Science 266 (1994) 66-71
116. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., and Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 13550-13555
117. Moelans C.B., de Weger R.A., van Blokland M.T.M., van der Wall E., and van Diest P.J. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Mod. Pathol. 23 (2010) 62-70
118. Moran R.E., Black M.M., Alpert L., and Straus M.J. Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer. Cancer 54 (1984) 1586-1590
119. Muss H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., Cirrincione C.T., Budman D.R., Wood W.C., Barcos M., and Henderson I.C. c-erB-2 expression and response to adjuvant therapy in women with node-positive early Breast cancer. N. Engl. J. Med. 330 (1994) 1260-1266
120. Normanno N., Bianco C., De Luca A., Maiello M.R., and Salomon D.S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10 (2003) 1-21
121. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Bramwell V.H., Andrulis I.L., and Pritchard K.I. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 101 (2009) 644-650
122. O'Shaugnessy J., Blackwell K.L., Burstein H., Storniolo A.M., Sledge G., Baselga J., Koehler M., Laabs S., Florance A., and Roychowdhury D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. (Suppl.) 26 (2008) 44s Abstr 1015
123. O'Shaugnessy J., Osborne C., Pippen J., Yoffe M., Patt D., Monaghan G., Rocha C., Ossovskaya V., Sherman B., and Bradley C. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J. Clin. Oncol. (Suppl.) 27 (2009) 793S Abstr 3
124. Ogston K.N., Miller I.D., Payne S., Hutcheon A.W., Sarkar T.K., Smith I., Schofield A., and Heys S.D. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12 (2003) 320-327
125. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., and Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 (2004) 2817-2826
126. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Wickerham D.L., and Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24 (2006) 3726-3734
127. Paik S.M., Bryant J., Park C.H., Fisher B., TanChiu E., Hyams D., Fisher E.R., Lippman M.E., Wickerham D.L., and Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90 (1998) 1361-1370
128. Palacios J., Robles-Frias M.J., Castilla M.A., Lopez-Garcia M.A., and Benitez J. The molecular pathology of hereditary breast cancer. Pathobiology 75 (2008) 85-94
129. Parker J.S., Mullins M., Cheang M.C.U., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X.P., Hu Z.Y., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., and Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27 (2009) 1160-1167
130. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., and Slamon D.J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15 (1997) 537-547
131. Penault-Llorca F., Andre F., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., Jacquemier J., Baranzelli M.C., Bibeau F., Antoine M., Lagarde N., Martin A.L., Asselain B., and Roche H. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27 (2009) 2809-2815
132. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge Ø., Pargamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.-L., Brown P.O., and Botstein D. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
133. Petit T., Borel C., Ghnassia J.-P., Rodier J.-F., Escande A., Mors R., and Haegelé P. Chemotherapy response of breast cancer depends on HER-status and antracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res. 7 (2001) 1577-1581
134. Petrek J.A., Naughton M.J., Case L.D., Paskett E.D., Naftalis E.Z., Singletary S.E., and Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J. Clin. Oncol. 24 (2006) 1045-1051
135. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., and Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
136. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M.J., Petersen R., Harpole D., Marks J., Berchuck A., Ginsburg G.S., Febbo P., Lancaster J., and Nevins J.R. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12 (2006) 1294-1300
137. Press M.F., Bernstein L., Sauter G., Zhou J.Y., Eiermann W., Pienkowski T., Crown J., Robert N., Bee V., Taupin H., Villalobos J., Seelig S., Pegram M., and Slamon D. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumqab (herceptin) in the adjuvant setting. Breast Cancer Res. Treat. 94 (2005) S54 Abstr 1045
138. Pritchard K.I., Shepherd L.E., O'Malley F.P., Andrulis I.L., Tu D.S., Bramwell V.H., and Levine M.N. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354 (2006) 2103-2111
139. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., El-Sayed M.E., Benhasouna A., Brunet J.S., Akslen L.A., Evans A.J., Blamey R., Reis J.S., Foulkes W.D., and Ellis I.O. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res. 15 (2009) 2302-2310
140. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., Dell'Orto P., Del Curto B., Henriksen K.L., Mastropasqua M.G., Price K.N., Mery E., Lacroix-Triki M., Braye S., Altermatt H.J., Gelber R.D., Castiglione-Gertsch M., Goldhirsch A., Gusterson B.A., Thurlimann B., Coates A.S., and Viale G. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 9 (2008) 23-28
141. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., Tamkus D., King K.M., Pajon E.R., Wright M.J., Robert J., Paik S., Mamounas E.P., and Wolmark N. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J. Clin. Oncol. 26 (2008) 778-785
142. Reinholz M.M., Bruzek A.K., Visscher D.W., Lingle W.L., Schroeder M.J., Perez E.A., and Jenkins R. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 10 (2009) 267-277
143. Rhiem K., Wappenschmidt B., Bosse K., Koppler H., Tutt A.N., and Schmutzler R.K. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. Clin. Oncol. 21 (2009) 448-450
144. Ring A.E., Smith I.E., Ashley S., Fulford L.G., and Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91 (2004) 2012-2017
145. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
146. Ross J.S., Fletcher J.A., Bloom K.J., Linette G.P., Stec J., Symmans W.F., Pusztai L., and Hortobagyi G.N. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3 (2004) 379-398
147. Rottenberg S., Jaspers J.E., Kersbergen A., van der Burg E., Nygren A.O., Zander S.A., Derksen P.W., de Bruin M., Zevenhoven J., Lau A., Boulter R., Cranston A., O'Connor M.J., Martin N.M., Borst P., and Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 17079-17084
148. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi G.N., and Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11 (2005) 5678-5685
149. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., Villegas E., Jacquemont C., Farrugia D.J., Couch F.J., Urban N., and Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1119
150. Salter K.H., Acharya C.R., Walters K.S., Redman R., Anguiano A., Garman K.S., Anders C.K., Mukherjee S., Dressman H.K., Barry W.T., Marcom K.P., Olson J., Nevins J.R., and Potti A. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLOS One 3 (2008) e1908
151. Scaltriti M., Verma C., Guzman M., Jimenez J., Parra J.L., Pedersen K., Smith D.J., Landolfi S., Cajal S.R.Y., Arribas J., and Baselga J. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28 (2009) 803-814
152. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., Delaney A., Gelmon K., Guliany R., Senz J., Steidl C., Holt R.A., Jones S., Sun M., Leung G., Moore R., Severson T., Taylor G.A., Teschendorff A.E., Tse K., Turashvili G., Varhol R., Warren R.L., Watson P., Zhao Y., Caldas C., Huntsman D., Hirst M., Marra M.A., and Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461 (2009) 809-813
153. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., Juul N., Leong C.O., Calogrias D., Buraimoh A., Fatima A., Gelman R.S., Ryan P.D., Tung N.M., De Nicolo A., Ganesan S., Miron A., Colin C., Sgroi D.C., Ellisen L.W., Winer E.P., and Garber J.E. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. (2010)
154. Sjøblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., and Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
155. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
156. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., and Press M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
157. Slamon D.J., LeylandJones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
158. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., Salter J., Clark E., Magill P., and Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 25 (2007) 3816-3822
159. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., and Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10393-10398
160. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B., Desmedt C., Larsimont D., Cardoso F., Peterse H., Nuyten D., Buyse M., Van de Vijver M.J., Bergh J., Piccart M.T., and Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98 (2006) 262-272
161. Stephens P.J., McBride D.J., Lin M.L., Varela I., Pleasance E.D., Simpson J.T., Stebbings L.A., Leroy C., Edkins S., Mudie L.J., Greenman C.D., Jia M.M., Latimer C., Teague J.W., Lau K.W., Burton J., Quail M.A., Swerdlow H., Churcher C., Natrajan R., Sieuwerts A.M., Martens J.W.M., Silver D.P., Langerod A., Russnes H.E.G., Foekens J.A., Reis-Filho J.S., van't Veer L., Richardson A.L., Borresen-Dale A.L., Campbell P.J., Futreal P.A., and Stratton M.R. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462 (2009) 1005-1060
162. Stratton M.R., Campbell P.J., and Futreal P.A. The cancer genome. Nature 458 (2009) 719-724
163. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J.T., Peeters M., van Tinteren H., van't Veer L.J., and Rodenhuis S. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat. 119 (2010) 551-558
164. Swaby R.F., and Jordan V.C. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin. Breast Cancer 8 (2008) 124-133
165. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., vandeRijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lønning P.E., and BorresenDale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10869-10874
166. Sørlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8418-8423
167. Sørlie T., Wang Y.L., Xiao C.L., Johnsen H., Naume B., Samaha R.R., and Borresen-Dale A.L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7 (2006)
168. Tan D.S.P., Marchio C., Jones R.L., Savage K., Smith I.E., Dowsett M., and Reis J.S. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat. 111 (2008) 27-44
169. Tan M.C., Al Mushawah F., Gao F., Aft R.L., Gillanders W.E., Eberlein T.J., and Margenthaler J.A. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am. J. Surg. 198 (2009) 520-525
170. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P., Wilking N., Nilsson J., and Bergh J. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 24 (2006) 2428-2436
171. Tassone P., Tagliaferri P., Perricelli A., Blotta S., Quaresima B., Martelli M.L., Goel A., Barbieri V., Costanzo F., Boland C.R., and Venuta S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88 (2003) 1285-1291
172. Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Halm M., Kramer H., Brors B., Rudlowski C., Benner A., Schuetz F., Tews B., Eils R., and Sinn H.P. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24 (2006) 1839-1845
173. Troester M.A., Herschkowitz J.I., Oh D.S., He X.P., Hoadley K.A., Barbier C.S., and Perou C.M. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6 (2006)
174. Turner N.C., Reis J.S., Russell A.M., Springall R.J., Ryder K., Steele D., Savage K., Gillett C.E., Schmitt F.C., Ashworth A., and Tutt A.N. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26 (2007) 2126-2132
175. Tutt A., Robson M.J.E.G., Domchek S., Audeh M.W., Weitzel J.N., Friedlander M.L., and Carmichael J. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. (Suppl.) 27 18S (2009) 803s (CRA501)
176. van 't Veer L., Dal H., van de Vijver M., He Y., Hart A., Mao M., Peterse H., van der Kooy K., Marton M., Witteveen A., Schreiber G., Kerkhoven R., Roberts C., Linsley P., Bernards R., and Friend S. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
177. van de Vijver M.J., He Y.D., van 't Veer L.J., Dai H., Hart A.A.M., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., and Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347 (2002) 1999-2009
178. Vincent-Salomon A., Rousseau A., Jouve M., Beuzeboc P., Sigal-Zafrani B., Freneaux P., Rosty C., Nos C., Campana F., Klijanienko J., Al Ghuzlan A., and Sastre-Garau X. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur. J. Cancer 40 (2004) 1502-1508
179. Wang J.Z., Buchholz T.A., Middleton L.P., Allred D.C., Tucker S.L., Kuerer H.M., Esteva F.J., Hortobagyi G.N., and Sahin A.A. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer 94 (2002) 3107-3114
180. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., and Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
181. Webster D.J.T., Bronn D.G., and Minton J.P. Estrogen receptors and response of breast cancer to chemotherapy. N. Engl. J. Med. 299 (1978) 604-605
182. Wessels L.F.A., van Welsem T., Hart A.A.M., van't Veer L.J., Reinders M.J.T., and Nederlof P.M. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res. 62 (2002) 7110-7117
183. West R.B., Nuyten D.S.A., Subramanian S., Nielsen T.O., Corless C.L., Rubin B.P., Montgomery K., Zhu S., Patel R., Hernandez-Boussard T., Goldblum J.R., Brown P.O., van de Vijver M., and van de Rijn M. Determination of stromal signatures in breast carcinoma. Plos Biol. 3 (2005) 1101-1110
184. Wong K.K., Fracasso P.M., Bukowski R.M., Lynch T.J., Munster P.N., Shapiro G.I., Jaenne P.A., Eder J.P., Naughton M.J., Ellis M.J., Jones S.F., Mekhail T., Zacharchuk C., Vermette J., Abbas R., Quinn S., Powell C., and Burris H.A. A Phase I Study with Neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 15 (2009) 2552-2558
185. Wooster R., Neuhausen S.L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D., Fields P., Marshall G., Narod S., Lenoir G.M., Lynch H., Feunteun J., Devilee P., Cornelisse C.J., Menko F.H., Daly P.A., Ormiston W., McManus R., Pye C., Lewis C.M., Cannonalbright L.A., Peto J., Ponder B.A.J., Skolnick M.H., Easton D.F., Goldgar D.E., and Stratton M.R. Localization of a breast-cancer susceptibility gene, Brca2, to Chromosome 13q12-13. Science 265 (1994) 2088-2090
186. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., Lewin-Koh N., Gunter B., Belvin M., Murray L.J., Friedman L.S., Sliwkowski M.X., and Hoeflich K.P. Suppression of HER2/HER3-Mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 15 (2009) 4147-4156
187. Yonemori K., Tsuta K., Shimizu C., Hatanaka Y., Hashizume K., Ono M., Kouno T., Ando M., Tamura K., Katsumata N., Hasegawa T., Kinoshita T., and Fujiwara Y. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med. Oncol. 26 (2009) 344-349
188. Young S.R., Pilarski R.T., Donenberg T., Shapiro C., Hammond L.S., Miller J., Brooks K.A., Cohen S., Tenenholz B., Desai D., Zandvakili I., Royer R., Li S., and Narod S.A. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9 (2009)
189. Yue W., Fan P., Wang J.P., Li Y.B., and Santen R.J. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106 (2007) 102-110